Electromed Appoints Peter Horwich as VP of Marketing to Boost Growth and Innovation

Electromed Strengthens Marketing Leadership with Peter Horwich Appointment

Electromed, Inc., a prominent player in airway clearance technologies, announces the appointment of Peter Horwich as Vice President of Marketing. With a robust background spanning over 20 years in the medical technology sector, Horwich brings a wealth of experience to the role. His previous position at Abiomed, now part of Johnson & Johnson MedTech, saw him spearheading global strategic marketing for Respiratory Therapies. Notably, he played a key role in the market introduction of the Breethe OXY-1 System™, which led to significant market expansion and revenue growth. This strategic hire signals Electromed's commitment to enhancing its marketing capabilities during a pivotal period of development.

Horwich's extensive experience at Medtronic, where he successfully launched various products and fostered market growth through innovative strategies, positions him as an ideal fit for Electromed. His track record in the industry is expected to bolster the company’s efforts to increase market penetration and adoption of its flagship product, the SmartVest Clearway. Electromed's CEO, Jim Cunniff, expresses his enthusiasm for Horwich’s arrival, emphasizing the importance of enhancing brand presence and customer engagement in a competitive landscape.

As Electromed continues to focus on driving strategic growth initiatives, Horwich’s leadership is crucial in optimizing return on investment and achieving the company’s revenue growth goals. The SmartVest® Airway Clearance System, designed for patients with compromised pulmonary function, stands at the forefront of Electromed's offerings. With Horwich at the helm of marketing, the company aims to unlock its potential in an under-penetrated market, ultimately enhancing shareholder value and solidifying its position as a leader in airway clearance therapy.

In related news, Electromed's ongoing commitment to innovation and patient care remains evident. The company, founded in 1992, continues to invest in research and development to improve its product offerings. As it navigates the complexities of the healthcare landscape, the integration of Horwich's expertise will likely play a pivotal role in shaping Electromed’s future directions and strategies. For more insights into Electromed’s advancements, interested parties can visit the company’s website at www.smartvest.com.